CYP19A1 and breast carcinoma: Gains in RET expression have been reported in multiple in vitro models of endocrine therapy-resistant breast cancer, including long-term estrogen deprived [7], tamoxifen-resistant [58, 59], and aromatase-overexpressing [68] breast cancer cell lines.